D3 N.E.

SUMMARY OF THE INVENTION

On page 2, the paragraph beginning on line 15 should read:

For the production of an antibody according to the invention, mRNA from freshly subcloned hybridoma cells of OKT3 is used as a basis. The cDNA is produced according to methods known to a person skilled in the art, which were described in Dübel et al., J. Immunol. Methods 175, pp. 89-95 91994), for example. The DNA coding for the variable domain of the light chain can be produced by means of PCR using suitable primers, e.g. by means of primers Bi5 (5'-GGGAAGATGGATCCAGTTGGTGCAGCATCAGC (SEQ ID NO:8)) and Bi8 (5'-GGTGATATCGTKCTCACYCARTCTCCAGCAAT (SEQ ID NO:9)) which hybridize to the amino-terminal part of the constant domain of the κ-chain and the framework1 (FR1) region of the variable domain of the κ-chain (Dübel et al., see above). For the amplification of the DNA which codes for the variable domain of the heavy chain, it is possible to use e.g. the primer Bi4 (5'-CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTCGTTTT (SEQ ID NO:10)) which hybridizes to the amino-terminal part of the constant domain 1 of the γ-chain (Dübel et al., cf. above) and the primer Bi3f (5'-CAGCCGGCCATGGCGCAGGTSCAGCTGCAGSAGTCWGG (SEQ ID NO:11)) which hybridizes to the FR1 region of the heavy chain (Gotter et al., Tumor Targeting 1, pp. 107-114 (1995).

D4

On page 4, the following heading is under the fourth paragraph, following the line "figures.":

D5

DESCRIPTION OF THE FIGURES

On page 5, the paragraph beginning on line 17 should read:

D6

Figures 3A and 3B: bispecific antibody composed of mutated OKT3 and anti-CD19.